VJOncology is committed to improving our service to you

ESMO 2019 | POLARIS: encorafenib/binimetinib for advanced BRAFV600+ melanoma

VJOncology is committed to improving our service to you

Georgina Long

Georgina Long, MD, PhD, FRACP, University of Sydney, Sydney, Australia, talks to us about the ongoing POLARIS trial (NCT03911869). The trial aims to investigate how encorafenib, a BRAF inhibitor, combined with the MEK inhibitor binimetinib interacts in the brain of patients with advanced melanoma and active brain metastasis. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter